Valneva SE
PAR:VLA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.892
5.31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Valneva SE
Valneva SE
Total Liabilities & Equity
Valneva SE
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities & Equity
€466.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Total Liabilities & Equity
€93.9m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities & Equity
€194.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
10%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities & Equity
€39.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Liabilities & Equity
€316.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
35%
|
CAGR 10-Years
22%
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Total Liabilities & Equity
€140.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Valneva SE
Glance View
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
See Also
What is Valneva SE's Total Liabilities & Equity?
Total Liabilities & Equity
466.6m
EUR
Based on the financial report for Sep 30, 2024, Valneva SE's Total Liabilities & Equity amounts to 466.6m EUR.
What is Valneva SE's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 1Y
-10%
Over the last year, the Total Liabilities & Equity growth was -10%.
You don't have any saved screeners yet
